Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002585 · ClinicalTrials.gov registry record · Phase 2
Pyrazoloacridine in Treating Women With Metastatic Breast Cancer
A Phase 2 study, sponsored by Barbara Ann Karmanos Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT00002585 is a Phase 2 study that has completed, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 20 participants.
The verdict
NCT00002585, a Phase 2 study, has completed, sponsored by Barbara Ann Karmanos Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of pyrazoloacridine in treating women with metastatic breast cancer.
Interventions
- DRUG pyrazoloacridine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 1994-02 |
| Est. Completion | 2001-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002585
The ClinicalTrials.gov registry entry for NCT00002585 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which pyrazoloacridine is the first listed.
NCT00002585 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002585 about?
NCT00002585 is a clinical study titled "Pyrazoloacridine in Treating Women With Metastatic Breast Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of pyrazoloacridine in treating women with metastatic breast cancer.
What is the current status of trial NCT00002585?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 1994-02. Estimated completion is 2001-01.
What interventions are being tested in trial NCT00002585?
The interventions under investigation include: pyrazoloacridine (DRUG).
Who is sponsoring clinical trial NCT00002585?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.